SOLARA ACTIVE PHARMA, A Pure API Player with vision for CRAMS
Brief Background Arun Kumar, who is a common promoter for Strides Shasun and Sequent Scientific (both are listed in the market) decided to create a new company which would focus purely on APIs, as the APIs were low margin business and making it difficult to maintain margin, with this goal in mind he demerged the low margin API(Ibuprofen, Gabapentin, and Ranitidine, etc..) business of Strides Shasun and Human API business of Sequent Scientific to create SOLARA ACTIVE PHARMA, which would be a pure API company. In March 2017, the board of directors of Strides and Sequent approved the demerger, and in March 2018, the scheme got approved by NCLT and the company got listed on June 27, 2018. According to the deal, for every 6 shares held in Strides, 1 share of Solara was allotted and for every 25 shares held in Sequent, 1 share of Solara was allotted. Strides Shasun retained the formulation business and High Margin API business, and Sequent Scientific ...
Comments
Post a Comment